Open-label study of long-term safety, tolerability, and efficacy of TEV-50717 (deutetrabenazine) for the treatment of dyskinesia in cerebral palsy in children and adolescents (RECLAIM-DCP open)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC
- Phase: III
- Execution start: 12/12/2019
- End of execution: 28/02/2022
- PI: ROCIO POZUELO CALVO